Issue 8, 2016

Metal-based drugs that break the rules


Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are applied in the majority of anticancer chemotherapeutic regimens. The success of these compounds has biased the approaches used to discover new metal-based anticancer drugs. In this perspective we highlight compounds that are apparently incompatible with the more classical (platinum-derived) concepts employed in the development of metal-based anticancer drugs, with respect to both compound design and the approaches used to validate their utility. Possible design approaches for the future are also suggested.

Graphical abstract: Metal-based drugs that break the rules

Article information

Article type
07 Oct 2015
05 Jan 2016
First published
28 Jan 2016
This article is Open Access
Creative Commons BY license

Dalton Trans., 2016,45, 3201-3209

Author version available

Metal-based drugs that break the rules

C. S. Allardyce and P. J. Dyson, Dalton Trans., 2016, 45, 3201 DOI: 10.1039/C5DT03919C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity